Myo-inositol is a promising treatment for the prevention of ovarian hyperstimulation syndrome (OHSS): an animal study

Archives of Gynecology and Obstetrics

Volumn 292, Issue 5, 2015, Pages 1163-1171

  Turan, Guluzar Arzu ^a   Eskicioglu, Fatma ^b   Sivrikoz, Oya Nermin ^a   Cengiz, Hakan ^a,c   Adakan, Saban ^a   Gur, Esra Bahar ^a   Tatar, Sumeyra ^a   Sahin, Nur ^a   Yilmaz, Osman ^c  

^a SIFA UNIVERSITY   (Turkey)

^b CELAL BAYAR UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Metformin; Myo inositol; Ovarian hyperstimulation syndrome; Pigment epithelium derived factor; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; INOSITOL; METFORMIN; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN; CYCLOOXYGENASE 1; ESTRADIOL; MEMBRANE PROTEIN; PTGS1 PROTEIN, RAT; VASCULOTROPIN A; VITAMIN B COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; ORGAN WEIGHT; OVARY DIAMETER; OVARY HYPERSTIMULATION; OVARY WEIGHT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; UPREGULATION; WEIGHT GAIN; WISTAR RAT; ANIMAL; DISEASE MODEL; METABOLISM; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION;

ANIMALS; CYCLOOXYGENASE 1; DISEASE MODELS, ANIMAL; ESTRADIOL; FEMALE; INOSITOL; MEMBRANE PROTEINS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITAMIN B COMPLEX;

EID: 84942980802     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-015-3747-5     Document Type: Article

References (28)

1. Kumar P, Sait SF, Sharma A, Kumar M (2011) Ovarian hyperstimulation syndrome. J Hum Reprod Sci 4(2):70–75. doi:10.4103/0974-1208.86080
2. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A (2008) Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update 14(4):321–333
3. Fujii E, Irie K, OhbaK Ogawa A, Yoshioka T, Yamakawa M et al (1997) Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeabilityin Mouse skin. Naunyn Schmiedebergs Arch Pharmacol 356(4):475–480
4. Quintana R, Kopcow L, Marconi G, Young E, Yovanovich C, Paz DA (2008) Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Fertil Steril 90(4):1511–1516
5. Chuderland D, Ben-Ami I, Kaplan-Kraicer R, Grossman H, Komsky A, Satchi-Fainaro R et al (2013) Hormonal regulation of pigment epithelium-derived factor (PEDF) in granulosa cells. Mol Hum Reprod 19(2):72–81. doi:10.1093/molehr/gas046
6. Aboulghar M (2009) Prevention of OHSS. Reprod Biomed Online 19(1):33–42
7. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R (2002) Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 26(7):883–896
8. Fleming R (2006) The use of insulin sensitising agents in ovulation induction in women with polycystic ovary syndrome. Hormones (Athens) 5(3):171–178
9. Perales-Puchalt A, Legro RS (2013) Ovulation induction in women with polycystic ovary syndrome. Steroids 78(8):767–772. doi:10.1016/j.steroids.2013.05.005
10. Khattab S, Fotouh IA, Mohesn IA, Metwally M, Moaz M (2006) Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach. Reprod Biomed Online 13(2):194–197
11. Sun X, Zhang D, Zhang W (2013) Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet 288(2):423–430. doi:10.1007/s00404-013-2756-5
12. Croze ML, Soulage CO (2013) Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie 95(10):1811–1827. doi:10.1016/j.biochi.2013.05.011
13. Bizzarri M, Carlomagno G (2014) Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 18(13):1896–1903
14. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C et al (2007) Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 23(12):700–703
15. Elia EM, Quintana R, Carrere C, Bazzano MV, Rey-Valzacchi G, Paz DA et al (2013) Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study. J Ovarian Res 6(1):62. doi:10.1186/1757-2215-6-62
16. Liu X, Chen HH, Zhang LW (2013) Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy. Int J Ophthalmol 6(283):221–227. doi:10.3980/j.issn.2222-3959.2013.02.22
17. Chuderland D, Ben-Ami I, Kaplan-Kraicer R, Grossman H, Ron-El R, Shalgi R (2013) The role of pigment epithelium-derived factor in the pathophysiology and treatment of ovarian hyperstimulation syndrome in mice. J Clin Endocrinol Metab 98(258):E258–E266
18. Cappelli V, Di Sabatino A, Musacchio MC, De Leo V (2013) Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS. Minerva Ginecol 65(4):425–433
19. Le Donne M, Alibrandi A, Giarrusso R (2012) Lo Monaco I, Muraca U. Diet, metformin and inositol in overweight and obese women with polycystic ovarysyndrome: effects on body composition. Minerva Ginecol 64(1):23–29
20. Sivalingam VN, Myers J, Nicholas S, Balen AH, Crosbie EJ (2014) Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. Hum Reprod Update 20(6):853–868. doi:10.1093/humupd/dmu037
21. Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Freitas V (2014) Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 11:CD006105
22. Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M et al (2013) Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 29(4):375–379. doi:10.3109/09513590.2012.743020
23. Colazingari S, Treglia M, Najjar R, Bevilacqua A (2013) The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet 288(6):1405–1411. doi:10.1007/s00404-013-2855-3
24. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L (2009) Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 91(5):1750–1754
25. Kasum M, Vrcic H, Stanic P, Jezek D, Oreškovic S, Beketic-Oreškovic L et al (2014) Dopamine agonists in prevention of ovarian hyperstimulation syndrome. Gynecol Endocrinol 30(12):845–849. doi:10.3109/09513590.2014.943716
26. Ferrero H, García-Pascual CM, Gaytán M, Morales C, Simón C, Gaytán F et al (2014) Dopamine receptor 2 activation inhibits ovarian vascular endothelial growth factor secretion in an ovarian hyperstimulation syndrome (OHSS) animal model: implications for treatment of OHSS with dopamine receptor 2 agonists. Fertil Steril 102(5):1468–1476. doi:10.1016/j.fertnstert.2014.07.1240
27. Martinez MC, Ruiz FJ, García-Velasco JA (2013) GnRH-agonist triggering to avoid ovarian hyperstimulation syndrome: a review of the evidence. Curr Drug Targets 14(8):843–849
28. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J et al (2011) Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev (5):CD001750. doi:10.1002/14651858.CD001750.pub3